News – Page 1067 – Endpoints News

SIGN UP

Alexion lines up $40M upfront deal with Halozyme to develop a better, easier next-gen followup to Soliris

8 years ago

Sage triggers another burst of investor enthusiasm as oral depression drug scores in PhII

8 years ago

Spark, Pfizer pass another milestone with impressive results treating hemophilia B

8 years ago

There are 2,004 cancer immunotherapies crowding into the pipeline. Now what?

8 years ago

Rich Heyman's Metacrine grabs a $22M round in search of a superior NASH drug

8 years ago

Looking for a come-from-behind win, Roche touts its pivotal success for Tecentriq combo in front-line lung cancer

8 years ago

More efficient rare pediatric drug development: FDA drafts guidance

8 years ago

Athyrium raises $2B for debt/equity fund; Amgen teams with Carmot on Parkinson's; Neuralstem soars on failed study(?)

8 years ago

Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA

8 years ago

Madrigal's stock soars on promising PhII data in NASH, but questions linger

8 years ago

Cancer R&D tips the scales at the FDA as active INDs climb to record high

8 years ago

After building expectations, the UK’s life sciences plan falls short of the hype

8 years ago

Looking for the next big breakthrough in CAR-T, Mike Gilman debuts Obsidian with $49.5M round

8 years ago

Clinical trial transparency improves at (some) biopharmas as J&J, Sanofi lead a pack trailed by Valeant and Allergan

8 years ago

Merck and PhRMA to FDA: Wait for ICH before finalizing guidance on toxicity testing for cancer drugs

8 years ago

In a blow to Eli Lilly, Novo Nordisk lands FDA OK for their next big entry in the diabetes market: Ozempic

8 years ago

Cellectis recruits ex-Servier research chief Depil; Arena inks $224M deal on new drugs; JLABS heads to Shanghai; ...

8 years ago

Analysts’ top 10 biotech takeover targets are concentrated in two key areas

8 years ago

Galectin PhIIb NASH trial fails the primary goal, but researchers hammer on the positive

8 years ago

Watch out Allergan: Revance’s wrinkle-reducer beats Botox in PhIII trials

8 years ago

Philippine health officials order Sanofi to halt Dengvaxia sales as controversy over health threat swells

8 years ago

Biopharma's top 10 overseas cash hoards. And what kind of M&A spree would $171B buy?

8 years ago

Michael Pellini has just joined Bill Maris at Section 32 — focused on patient care and drug development

8 years ago

Ra Pharma puts its best foot forward with PhII Soliris rival, but shares crash after comparison to Alexion’s ...

8 years ago

First page Previous page 1064 1065 106610671068 1069 1070 Next page Last page